Author name: DrugPatentWatch

Part I: The Strategic Logic of Patent Due Diligence Why Pharma IP Is the Business, Not Just an Asset In […]

Every blockbuster drug carries two distinct asset classes: the molecule itself and the legal monopoly wrapped around it. The Patent

Introduction: Beyond the Crystal Ball – Forging Competitive Advantage in Pharma In the high-stakes world of pharmaceutical innovation, the chasm

Strategic Analysis of the South African Pharmaceutical Landscape The South African pharmaceutical market is the primary industrial and regulatory anchor

1. The Structural Dissolution of the Traditional Supply Chain The pharmaceutical industry has long relied on a fortress of opacity.

Introduction: The Patent Filing Is a Financial Document The global prescription drug market cleared $1.6 trillion in annual revenue by

The $236 Billion Opportunity Generic drugs fill roughly 90% of all U.S. prescriptions but account for only about 22% of

1. The Anatomy of a U.S. Drug Patent: Knowing the Battlefield The dominant narrative in pharmaceutical IP for most of

Chronic diseases kill 74% of all humans who die each year. That is not a warm-up statistic—it is the entire